These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32299819)

  • 1. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
    Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
    Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
    Tsuyoshi H; Yoshida Y
    Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
    Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets.
    Kim J; Kim JH; Kang HG; Park SY; Yu JY; Lee EY; Oh SE; Kim YH; Yun T; Park C; Cho SY; You HJ
    BMC Med Genet; 2018 Dec; 19(Suppl 1):216. PubMed ID: 30598078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
    Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
    Oncologist; 2024 Jul; 29(7):560-565. PubMed ID: 38716772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
    Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA
    Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
    Xia Y; Wang L; Ma X; Li X
    Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis.
    Momeni-Boroujeni A; Yousefi E; Balakrishnan R; Riviere S; Kertowidjojo E; Hensley ML; Ladanyi M; Ellenson LH; Chiang S
    Mod Pathol; 2023 Apr; 36(4):100084. PubMed ID: 36788080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
    Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.
    Pan M; Ganjoo K; Karam A
    Perm J; 2021 May; 25():. PubMed ID: 33970096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22.
    Holzmann C; Koczan D; Loening T; Rommel B; Bullerdiek J
    Anticancer Res; 2017 May; 37(5):2233-2237. PubMed ID: 28476787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
    Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
    J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
    Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
    J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutics in the Treatment of Uterine Sarcoma.
    Bose S; Schwartz GK; Ingham M
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():900-909. PubMed ID: 35714303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation.
    Selenica P; Conlon N; Gonzalez C; Frosina D; Jungbluth AA; Beets-Tan RGH; Rao MK; Zhang Y; Benayed R; Ladanyi M; Solit DB; Chiang S; Hyman DM; Hensley ML; Soslow RA; Weigelt B; Murali R
    Am J Surg Pathol; 2021 Jan; 45(1):77-92. PubMed ID: 32889887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.